CENCORA INC

Explore how Cencora Inc.’s CFO retirement and strategic focus on tech‑driven value‑based care shape its growth and resilience in today’s evolving healthcare market.

Read how Cencora’s partnership with Acclinate’s NOWINCLUDED platform boosts inclusive clinical trials, diversifying data, accelerating approvals, and driving ESG value.

Explore Cencora Inc.’s dividend hike, market performance vs. the S&P 500, and how QIVIGY®’s nationwide launch reflects broader pharma growth.

Explore how Cencora’s $3.5 B merger with Covetrus reshapes veterinary distribution—boosting market share, cutting costs, and driving revenue growth through tech‑enabled care.

Explore how Cencora’s $3 bn senior note issuance and Goldman Sachs’s stake boost its growth strategy, impact leverage, and create a flexible, long‑term capital base.

Read how Cencora’s new board hire, Ellen G. Cooper, strengthens risk oversight and drives long‑term growth, while routine investor moves keep the stock steady.

Explore why analysts are bullish on Cencora Inc., the impact of board addition Ellen Cooper, and how the firm’s growth, governance and market dynamics shape future value.

Corporate update on Cencora Inc.: Q1 2026 earnings release date disclosed, with Bank of America cutting its price target amid valuation concerns and shifting growth outlook.

Explore Cencora’s rising stock, robust pipeline and cost‑effective therapies, including FDA‑approved Product A, to boost patient outcomes and investor confidence.

Insider sale by Silvana Battaglia at Cencora Inc. reveals market sensitivity; 1.2 M shares sold at $45.30, sparking analyst debate on governance and investor confidence.